Uroplasty broadens neuromodulation patent portfolio

Jul 1 2010

Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,729,772 which covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve.  The neuromodulation system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.

"We are very pleased to have this new patent added to our overall intellectual property portfolio," said David Kaysen, President and CEO.  "This newly-issued patent broadens our portfolio of neuromodulation patents, which includes patents covering our Urgent® PC System, a product we have commercialized in the U.S. since 2006 for the treatment of urinary urgency, urinary frequency, and urinary urge incontinence. While we have not begun work on nor have any current plans for product development related to this implantable neuromodulation patent, this newly-issued patent could offer an opportunity to broaden our product offering."

SOURCE Uroplasty, Inc.